Reprint
Hereditary Hemorrhagic Telangiectasia
Recent Advances and Future Challenges
Edited by
May 2021
228 pages
- ISBN978-3-0365-0590-9 (Hardback)
- ISBN978-3-0365-0591-6 (PDF)
This book is a reprint of the Special Issue Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disease that affects the blood vessels, and is characterized by direct connections between arteries and veins with no intervening capillaries. These abnormal vessels may appear in the skin as tiny red dilated blood vessels in the mouth, lips, fingers and toes. The presence of these vascular lesions in the mucosa can lead to spontaneous and recurrent nose bleeding, typically beginning in mid-childhood, and this is the most common clinical manifestation of HHT, occurring in over 90% of patients. Gastrointestinal bleeding, derived from mucocutaneous vascular lesions, affects approximately 25% of patients, almost always presenting after the age of 50. Chronic nasal and gastrointestinal bleeding can cause iron-deficiency anemia, and current therapeutic strategies are trying to minimize iron and blood transfusions. HHT patients also present large vascular lesions, known as arteriovenous malformations, that occur in internal organs like lungs, liver, and brain, and may result in life-threatening complications often related to the shunting of blood. This book not only highlights the current knowledge regarding diagnosis and treatment of HHT, but also the newest insights in the molecular basis of HHT, the understanding of which is essential for the development of new medicines or therapeutic strategies.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
hereditary hemorrhagic telangiectasia; rare diseases; telangiectasis; transforming growth factor-beta (TGF-β); Smad pathway; gastrointestinal bleeding; hereditary hemorrhagic telangiectasia; epistaxis; nosebleeds; tacrolimus; nasal ointment; genetic disease; rare disease; hereditary hemorrhagic telangiectasia (HHT); telangiectases; mechanical damage; sun-induced trauma; vascular malformations; Endoglin; activin-receptor-like kinase 1; Hereditary Hemorrhagic Telangiectasia; antithrombotic therapy; anticoagulants; antiplatelets; bleeding; safety; HHT; ALK1; endoglin; raloxifene; bazedoxifene; tranexamic acid; propranolol; FK506; etamsylate; N-acetylcysteine; pulmonary arteriovenous malformations; hereditary hemorrhagic telangiectasia; transcatheter embolotherapy; screening; guidelines; Hereditary hemorrhagic telangiectasia; pediatrics; genotype–phenotype correlation; arteriovenous malformation; ENG; ACVRL1; SMAD4; microRNA; biomarker; hereditary hemorrhagic telangiectasia (HHT); plasma; telangiectases; arteriovenous malformations (AVMs); angiogenesis; endoglin; activin receptor-like kinase 1 (ALK1); transforming growth factor beta (TGF-β); bone morphogenetic protein (BMP); hereditary hemorrhagic telangiectasia; epistaxis; propranolol gel; epistaxis severity score; nasal endoscopy; antiangiogenic properties; non-coding RNAs; microRNAs; long non-coding RNAs; hereditary hemorrhagic telangiectasia; biomarkers; endothelial cells; angiogenesis; hereditary hemorrhagic telangiectasia (HHT), second-hit; arteriovenous malformation (AVM); endoglin; ALK1; Smad4; inflammation; shear stress; vascular injury; somatic mutation; cell adhesion; angiogenesis; vascular endothelial growth factor (VEGF); transforming growth factor beta (TGF-β); telangiectasia; hereditary hemorrhagic; vascular malformations; survival; life expectancy; pulmonary arteriovenous malformation; contrast enhanced magnetic resonance angiography; hereditary hemorrhagic telangiectasia; HHT; liver; MRI; ultrasound; AVM; bevacizumab; Osler–Weber–Rendu; hereditary hemorrhagic telangiectasia/HHT/osler’s disease; cerebral ischemic lesions; catheter based embolization therapy; pulmonary arteriovenous malformations